Thermal Ablation for Treating Tumor-induced Osteomalacia in a Patient With IV Phosphate Dependency.

hypophosphatemic osteomalacia microwave ablation thermal ablation tumor-induced osteomalacia

Journal

JCEM case reports
ISSN: 2755-1520
Titre abrégé: JCEM Case Rep
Pays: England
ID NLM: 9918609886906676

Informations de publication

Date de publication:
Jul 2023
Historique:
received: 06 03 2023
medline: 1 11 2023
pubmed: 1 11 2023
entrez: 1 11 2023
Statut: epublish

Résumé

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome associated with tumors secreting fibroblast growth factor 23 that can be cured with complete surgical resection of the tumor. However, when these tumors are at difficult locations, less invasive modalities such as thermal ablation (TA) might be a good alternative. A 40-year-old woman was seen for a second opinion because of severe hypophosphatemia with complaints of fatigue, myalgia, and muscle weakness for which she needed IV phosphate for 15 to 18 hours per day in addition to oral alfacalcidol and phosphate. Initial laboratory results revealed hypophosphatemia (0.59 mmol/L [1.83 mg/dL]; reference range, 0.90-1.50 mmol/L [8.40-10.2 mg/dL]), increased fibroblast growth factor 23 levels (137 RU/mL; reference range, <125 RU/mL), and a reduced TmP-GFR (0.47 mmol/L; reference range, 0.8-1.4 mmol/L). Gallium-positron emission tomography/computed tomography (CT) showed moderately increased uptake at thoracic vertebra (Th) 8 and mildly increased uptake at Th7, suggestive of TIO. Complete tumor removal would have required resection of at least 1 vertebral body. Therefore, CT-guided TA was performed at Th8. No complications were observed, and in the months after, treatment with IV phosphate could be discontinued, indicating a satisfying result from the procedure. This extreme TIO case demonstrates that CT-guided TA can be an alternative to extensive or risky classical surgery.

Identifiants

pubmed: 37908985
doi: 10.1210/jcemcr/luad086
pii: luad086
pmc: PMC10580436
doi:

Types de publication

Case Reports

Langues

eng

Pagination

luad086

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.

Références

Cancer. 1987 Apr 15;59(8):1442-54
pubmed: 3545439
J Intern Med. 2023 Mar;293(3):309-328
pubmed: 36511653
J Clin Endocrinol Metab. 2014 Sep;99(9):3049-54
pubmed: 24960541
J Vasc Interv Radiol. 2022 May;33(5):530-537.e1
pubmed: 35121096
Calcif Tissue Int. 2022 Oct;111(4):367-379
pubmed: 35857061
N Engl J Med. 2007 Jul 26;357(4):422-4
pubmed: 17652663
Orthop Clin North Am. 2006 Jul;37(3):475-84, viii
pubmed: 16846772
Osteoporos Int. 2023 Jan;34(1):201-206
pubmed: 35925260
J Clin Endocrinol Metab. 2013 Nov;98(11):4267-72
pubmed: 24014621
J Clin Endocrinol Metab. 2016 Oct;101(10):3575-3581
pubmed: 27533306

Auteurs

Evert F S van Velsen (EFS)

Department of Internal Medicine, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.
Erasmus MC Bone Center, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.

Tychon E A Geeraedts (TEA)

Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.

Ariadne Bosman (A)

Department of Internal Medicine, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.
Erasmus MC Bone Center, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.

M Carola Zillikens (MC)

Department of Internal Medicine, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.
Erasmus MC Bone Center, Erasmus University Medical Center, 3015 CE, Rotterdam, The Netherlands.

Classifications MeSH